Innovent Biologics (HKSE:01801) EPS (Basic) : HK$-0.72 (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics EPS (Basic)?

Innovent Biologics's basic earnings per share (Basic EPS) for the six months ended in Jun. 2023 was HK$-0.10. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.72.

Innovent Biologics's EPS (Diluted) for the six months ended in Jun. 2023 was HK$-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-0.72.

Innovent Biologics's EPS without NRI for the six months ended in Jun. 2023 was HK$-0.10. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -0.74.

During the past 3 years, the average EPS without NRI Growth Rate was -0.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Innovent Biologics's highest 3-Year average EPS without NRI Growth Rate was 50.50% per year. The lowest was -45.90% per year. And the median was -6.10% per year.

Innovent Biologics EPS (Basic) Historical Data

The historical data trend for Innovent Biologics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics EPS (Basic) Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.63

-0.88

-2.30

-1.63

-0.72

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial										-1.46	-0.76	-0.91	-0.10	-0.62

Innovent Biologics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Innovent Biologics's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2433.623	-	0)	/	1490.123
	=	-1.63

Innovent Biologics's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-152.198	-	0)	/	1535.321
	=	-0.10

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.72

Innovent Biologics (HKSE:01801) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Innovent Biologics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines